INDICATIONS AND USAGE（适应症）

CAPRELSA is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.

Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA.

DOSAGE（服用剂量）

The recommended dose of CAPRELSA is 300 mg taken orally once daily until disease progression or unacceptable toxicity occurs.

CAPRELSA may be taken with or without food.

Do not take a missed dose within 12 hours of the next dose.

Do not crush CAPRELSA tablets. The tablets can be dispersed in 2 ounces of water by stirring for approximately 10 minutes (will not completely dissolve). Do not use other liquids for dispersion. Swallow immediately after dispersion. Mix any remaining residue with 4 additional ounces of water and swallow.

The dispersion can also be administered through nasogastric or gastrostomy tubes.

ADVERSE REACTIONS（不良反应）

QT Prolongation and Torsades de Pointes

Severe Skin Reactions

Interstitial Lung Disease

Ischemic Cerebrovascular Events

Hemorrhage

Heart Failure

Diarrhea

Hypothyroidism

Hypertension

Reversible Posterior Leukoencephalopathy Syndrome

Embryo-Fetal Toxicity

For full information, please refer to:

https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/e5721cb8-4185-47b9-bbb3-1c587e558a03/spl-doc?hl=Vandetanib

LuciVandinformation